Damon Runyon Researchers

Meet Our Scientists
Bradley L. Pentelute, PhD

Antibodies have proven to be powerful tools in cancer research, facilitating the elucidation of disease mechanisms and generating novel and effective anti-cancer therapeutics. However, antibody biotechnology is limited by one major factor: the inability of antibodies to effectively cross the cell membrane to reach the inside of the cell, or cytosol. A new strategy is clearly necessary-one based on facile and reliable delivery of active antibody-like molecules into various cell types. 

Dr. Pentelute plans to construct a new, targeted delivery platform capable of introducing stable molecules that mimic antibodies (deemed "intrabodies"). He will use this proposed delivery platform to strike the intracellular cancer target Bcr-Abl for treatment of chronic myeloid leukemia. He also aims to target the cancer-promoting complex p53/MDM2 in cancer cells. Through these innovative studies, he aims to advance the frontier by delivering a diverse array of antibody-like molecules into cells for cancer therapy. 


Project title: "Striking cancer with intracellular antibodies"
Institution: Massachusetts Institute of Technology
Award Program: Innovator
Cancer Type: All Cancers
Research Area: Chemical Biology